Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.
Where this comes from
- Record sourced from PubMed, PMID 38754067.
- Also identified by DOI 10.1200/JCO.24.00279 and PMC identifier 11457111.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.
Medical subject headings
- Neoplasm Recurrence, Local
- Prostatic Neoplasms